Acasti Pharma Inc. is a Canada-based biopharmaceutical company focused on the research, development and commercialization of new krill-oil based forms of omega-3 phospholipid therapies for the treatment and prevention of certain cardiometabolic disorders, in particular abnormalities in blood lipids, referred to as dyslipidemia. The Company owns a prescription drug candidate, CaPre, as well as a medical food, Onemia, which is available in the market. The Company is conducted a Phase II open label (COLT) study, the results of, which showed that CaPre was safe and effective in reducing triglycerides in patients with mild to severe hypertriglyceridemia. It is conducting a Phase II double blind (TRIFECTA) trial on CaPre to evaluate the safety and efficacy of CaPre on patients with hypertriglyceridemia. The Company is also conducting a Pharmacokinetics trial on CaPre in collaboration with Quintiles.